Capricor's Deramiocel Faces FDA Advisory Panel July 29 After 67% Crash — Two Competing Analysis Plans Are the Whole Fight

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) convenes July 29, 2026, to vote on BLA 125842 — deramiocel, human allogeneic cardiosphere-derived cells, for cardiomyopathy in Duchenne muscular dystrophy. The FDA's formal answer comes August 22, 2026, the PDUFA target action date.

On July 27, 2026, CAPR fell 67.4% to $6.42, wiping out roughly $766 million in equity value and leaving market capitalization at approximately $370 million, per reporting from ts2.tech and stockanalysis.com. B. Riley downgraded the stock to Neutral from Buy that session, cutting its price target to $10 from $63.

The catalyst was the FDA's own briefing documents, which cast significant doubt on the efficacy data ahead of today's panel. The core dispute: which statistical analysis plan governs the HOPE-3 Phase 3 trial results.

Capricor's position is that HOPE-3 achieved statistical significance on its primary endpoint (PUL v2.0), the key secondary cardiac endpoint (LVEF), and all other Type I error-controlled secondary endpoints under SAP version 3.0 — the final analysis plan the company says was locked before unblinding. The FDA's briefing materials, however, show that planned analyses for arm and heart function did not achieve statistical significance. Capricor's counter: those FDA analyses rely on SAP version 1.1, which the company describes as an unsigned, incomplete internal draft. That disagreement over which document controls the trial is the entire scientific argument before the panel.

CEO Linda Marbán framed the company's case in its June 26, 2026 news release: "We have confidence in the totality of evidence supporting Deramiocel, which has demonstrated clinically meaningful, statistically significant skeletal and cardiac benefits with a consistent safety profile, across multiple studies supporting its potential as a first-in-class therapy for Duchenne muscular dystrophy."

The BLA draws on data from the Phase 2 HOPE-2 trial, long-term follow-up from the HOPE-2-OLE extension, and HOPE-3. No approved therapy has been shown to slow cardiac function decline in DMD. Cardiomyopathy — the indication under review — is described in allsci.com's regulatory coverage as the primary cause of mortality in DMD through dilated cardiomyopathy, heart failure, and arrhythmia, with existing approved DMD therapies not systematically studied for cardiac effects.

On the regulatory tailwinds side, deramiocel holds Orphan Drug Designation from both the FDA and the European Medicines Agency, Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S., Advanced Therapy Medicinal Product (ATMP) designation in Europe, and Rare Pediatric Disease Designation from the FDA — the last of which may qualify Capricor for a Priority Review Voucher upon approval, per the company's June 26, 2026 news release.

The committee's vote is advisory only. The FDA retains ultimate decision-making authority and is not bound by the panel's recommendation. Whatever the panel concludes July 29, the August 22 PDUFA date is when the agency's formal answer arrives.